Label-free cell viability assays using phase imaging with computational specificity
Ended Project Grant Awarded Last action
- Award ID
- R44GM145168
- Recipient
-
Phi Optics Inc. UEI F277MVZW7B15
- Awarding agency
-
National Institute of General Medical Sciences
National Institutes of Health, Department of Health and Human Services
- Obligated
- $2,273,622
Award facts
- Assistance listing
- 93.859 Biomedical Research and Research Training
- Completion date
- Place of performance
- Champaign, IL 61820, USA
Award details come from USAspending.gov.
Description
- Abstract
- Viable cell concentration is one of the most important key performance indicator during upstream technologies in mammalian cell culture. Customer discovery discussions with biopharma execs and r & d specialists revealed there is an unmet need for on-line/in-line monitoring of cell viability in pharma bioreactors driven by compliance with real-time product quality assurance as described in process analytical technology (PAT) and quality by design initiatives. Preliminary work equivalent to phase i effort has resulted in a cell imaging system including a flow cell setup that simulates an on-line stirring bioreactor sampling route. Proof-of-concept was also established for detection and classification of live/dead assays using digital staining via pics (phase imaging with computational specificity). This small business innovation research project proposes to build a commercial prototype instrument for real time, quantitative and high-throughput cell viability scoring for on-line/in-line bioreactor monitoring that meets the metrics of interest for pharma r & d applications. During this effort the standard operation of the QPI+pics instrument will be refined and the automated software detection and classification of live/dead assays will be completed. At the end of this direct phase II project we will deliver a commercial prototype -a "push-of-a-button" viability scanner with the above capabilities built in.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | -$164,889 | |
| Amendment | $649,893 | |
| Amendment | $894,309 | |
| Original award | $894,309 |
Quick answers
Who received award R44GM145168?
R44GM145168 was awarded to Phi Optics Inc. by National Institute of General Medical Sciences (National Institutes of Health) on May 10, 2022.
How much is award R44GM145168 worth?
$2,273,622 has been obligated on R44GM145168.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award